| Phase transitions in biogenic amorphous calcium carbonate YUT Gong, CE Killian, IC Olson, NP Appathurai, AL Amasino, MC Martin, ... Proceedings of the National Academy of Sciences 109 (16), 6088-6093, 2012 | 308 | 2012 |
| Mechanism of calcite co-orientation in the sea urchin tooth CE Killian, RA Metzler, YUT Gong, IC Olson, J Aizenberg, Y Politi, FH Wilt, ... Journal of the American Chemical Society 131 (51), 18404-18409, 2009 | 208 | 2009 |
| Prognostic value of the lung immune prognostic index for patients treated for metastatic non–small cell lung cancer D Kazandjian, Y Gong, P Keegan, R Pazdur, GM Blumenthal JAMA oncology 5 (10), 1481-1485, 2019 | 190 | 2019 |
| FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer S Arora, S Balasubramaniam, H Zhang, T Berman, P Narayan, D Suzman, ... The oncologist 26 (1), e164-e172, 2021 | 135 | 2021 |
| FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1 P Narayan, S Wahby, JJ Gao, L Amiri-Kordestani, A Ibrahim, E Bloomquist, ... Clinical cancer research 26 (10), 2284-2289, 2020 | 120 | 2020 |
| FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer P Narayan, TM Prowell, JJ Gao, LL Fernandes, E Li, X Jiang, J Qiu, J Fan, ... Clinical Cancer Research 27 (7), 1842-1849, 2021 | 105 | 2021 |
| FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma E Chang, C Weinstock, L Zhang, R Charlab, SE Dorff, Y Gong, V Hsu, F Li, ... Clinical cancer research 27 (4), 922-927, 2021 | 105 | 2021 |
| Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer GM Blumenthal, Y Gong, K Kehl, P Mishra-Kalyani, KB Goldberg, ... Annals of Oncology 30 (5), 830-838, 2019 | 100 | 2019 |
| Self‐sharpening mechanism of the sea urchin tooth CE Killian, RA Metzler, Y Gong, TH Churchill, IC Olson, V Trubetskoy, ... Advanced Functional Materials 21 (4), 682-690, 2011 | 95 | 2011 |
| Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton … T Giaddui, W Chen, J Yu, L Lin, CB Simone, L Yuan, YUT Gong, QJ Wu, ... Radiation oncology 11, 1-7, 2016 | 90 | 2016 |
| Systematic review of PD-1/PD-L1 inhibitors in oncology: from personalized medicine to public health E Chang, L Pelosof, S Lemery, Y Gong, KB Goldberg, AT Farrell, ... The Oncologist 26 (10), e1786-e1799, 2021 | 64 | 2021 |
| FDA Approval summary: Pembrolizumab, atezolizumab, and cemiplimab-rwlc as single agents for first-line treatment of Advanced/Metastatic PD-L1–high NSCLC O Akinboro, E Larkins, LH Pai-Scherf, LN Mathieu, Y Ren, J Cheng, ... Clinical Cancer Research 28 (11), 2221-2228, 2022 | 51 | 2022 |
| Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation … DJ Pinato, TU Marron, PS Mishra-Kalyani, Y Gong, G Wei, D Szafron, ... European Journal of Cancer 157, 140-152, 2021 | 51 | 2021 |
| FDA approval summary: tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer M Shah, S Wedam, J Cheng, MH Fiero, H Xia, F Li, J Fan, X Zhang, J Yu, ... Clinical Cancer Research 27 (5), 1220-1226, 2021 | 51 | 2021 |
| FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer MS Anscher, E Chang, X Gao, Y Gong, C Weinstock, E Bloomquist, ... The Oncologist 26 (2), 139-146, 2021 | 49 | 2021 |
| Trends in the approval of cancer therapies by the FDA in the twenty-first century EC Scott, AC Baines, Y Gong, R Moore Jr, GE Pamuk, H Saber, ... Nature Reviews Drug Discovery 22 (8), 625-640, 2023 | 43 | 2023 |
| FDA approval summary: pertuzumab, trastuzumab, and hyaluronidase–zzxf injection for subcutaneous use in patients with HER2-positive breast cancer JJ Gao, CL Osgood, Y Gong, H Zhang, EW Bloomquist, X Jiang, J Qiu, ... Clinical Cancer Research 27 (8), 2126-2129, 2021 | 28 | 2021 |
| Validation of a rectal cancer outcome prediction model with a cohort of Chinese patients L Shen, J van Soest, J Wang, J Yu, W Hu, YUT Gong, V Valentini, Y Xiao, ... Oncotarget 6 (35), 38327, 2015 | 21 | 2015 |
| Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials Y Gong, KL Kehl, GR Oxnard, S Khozin, PS Mishra-Kalyani, ... Journal of Clinical Oncology 36 (suppl), abstr 9064, 2018 | 19 | 2018 |
| Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US Food and Drug Administration trial-level and patient-level analyses KJ Norsworthy, X Gao, CW Ko, ED Pulte, J Zhou, Y Gong, YL Shen, ... Journal of Clinical Oncology 40 (8), 847, 2022 | 16 | 2022 |
